Overview
Syndromic oculocutaneous albinism (OCA) refers to a group of rare genetic conditions where reduced or absent pigmentation of the skin, hair, and eyes (oculocutaneous albinism) occurs alongside other medical problems affecting different body systems. Unlike non-syndromic albinism, which mainly affects pigmentation and vision, syndromic forms come with additional health issues that can vary widely depending on the specific underlying condition. Well-known examples include Hermansky-Pudlak syndrome (HPS), Chediak-Higashi syndrome (CHS), and Griscelli syndrome. People with syndromic OCA typically have very light skin, hair, and eye color from birth, along with significant vision problems such as reduced visual sharpness, sensitivity to light, and involuntary eye movements (nystagmus). Depending on the specific syndrome, additional features may include bleeding problems due to platelet dysfunction, immune system deficiency leading to frequent infections, lung fibrosis, inflammatory bowel disease, or neurological problems. Treatment is tailored to the specific syndrome and its complications. There is currently no cure for any form of syndromic OCA. Management focuses on protecting the skin and eyes from sun damage, correcting vision as much as possible, managing bleeding tendencies, treating infections promptly, and addressing organ-specific complications. Some patients with severe immune deficiency or blood disorders may require bone marrow transplantation. Early diagnosis and coordinated care from multiple specialists are essential for the best possible outcomes.
Key symptoms:
Very light or white hair from birthVery pale skin that burns easilyLight-colored eyes (blue, gray, or light brown)Reduced vision or legal blindnessInvoluntary eye movements (nystagmus)Sensitivity to bright lightEasy bruising or prolonged bleedingFrequent or severe infectionsLung scarring or breathing problemsInflammatory bowel disease or chronic diarrheaEnlarged liver or spleenNeurological problems such as poor coordination or developmental delaySilvery-gray hair (in some subtypes)Skin infections or slow wound healing
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Neonatal
Begins at or shortly after birth (first 4 weeks)
FDA & Trial Timeline
1 eventNational Human Genome Research Institute (NHGRI)
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Syndromic oculocutaneous albinism.
1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Specialists
View all specialists →No specialists are currently listed for Syndromic oculocutaneous albinism.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Syndromic oculocutaneous albinism.
Community
No community posts yet. Be the first to share your experience with Syndromic oculocutaneous albinism.
Start the conversation →Latest news about Syndromic oculocutaneous albinism
No recent news articles for Syndromic oculocutaneous albinism.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.Which specific type of syndromic oculocutaneous albinism does my child or I have, and what gene is involved?,What complications should I watch for based on this specific subtype?,Are there medications or over-the-counter drugs I should avoid because of bleeding risk?,How often should we have eye exams, lung function tests, and blood work?,Is bone marrow transplantation something we should consider, and if so, when?,Are there any clinical trials or new treatments being studied for this condition?,What resources or support groups can help our family cope with this diagnosis?
Common questions about Syndromic oculocutaneous albinism
What is Syndromic oculocutaneous albinism?
Syndromic oculocutaneous albinism (OCA) refers to a group of rare genetic conditions where reduced or absent pigmentation of the skin, hair, and eyes (oculocutaneous albinism) occurs alongside other medical problems affecting different body systems. Unlike non-syndromic albinism, which mainly affects pigmentation and vision, syndromic forms come with additional health issues that can vary widely depending on the specific underlying condition. Well-known examples include Hermansky-Pudlak syndrome (HPS), Chediak-Higashi syndrome (CHS), and Griscelli syndrome. People with syndromic OCA typically
How is Syndromic oculocutaneous albinism inherited?
Syndromic oculocutaneous albinism follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Syndromic oculocutaneous albinism typically begin?
Typical onset of Syndromic oculocutaneous albinism is neonatal. Age of onset can vary across affected individuals.
Are there clinical trials for Syndromic oculocutaneous albinism?
Yes — 1 recruiting clinical trial is currently listed for Syndromic oculocutaneous albinism on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.